Slide 1: Exchange cover letter: Investor Presentation August 2024
Ref No.: ZLL/CS/BSE/NSE Date: 30.08.2024 BSE Limited, National Stock Exchange of India Limited Market Operations Dept. Listing Compliance Department P. J. Towers, Dalal Street, Exchange Plaza, Bandra-Kurla Complex, Mumbai- 400 001 Bandra (E), Mumbai – 400 051 Company Code- 541400 (Symbol - ZIMLAB) D
Slide 2: Investor Presentation – August 2024
ZIM LABORATORIES LIMITED INVESTOR PRESENTATION – AUGUST 2024
Slide 3: Safe Harbour
SAFE HARBOUR The presentation has been prepared by ZIM Laboratories Limited (“ZIM” or the “Company”) solely for information purposes and does not constitute an offer to sell or recommendation or solicitation of an offer to subscribe for or purchase any securities and nothing contained herein shall f
Slide 4: Integrated Business Model
INTEGRATED BUSINESS MODEL Business Distinct Offerings End-to-End Product Development Segments Across therapy segments and Dosage forms Offerings Therapy Segments Conceptualisation involves R&D Tablets Anti - Infective 01. Product Conceptualisation Export o FF and product research to examine feasibil
Slide 5: Business Review
BUSINESS REVIEW Focus on Innovative Committed Products to enhancing & Strategic Business Mix andPartnerships Geographic Mix • 6 NIP filed in EU till date, from this Azithromycin Oral Susp. MA received Innovative Products • Sildenafil and Ondansetron commercialized in Europe and Canada Strategy • MA
Slide 6: Committed to Core Strategy
COMMITTED TO CORE STRATEGY Pharma : Nutra Mix % Exports Mix % Pharmaceuticals Nutraceuticals Exports Domestic 77% vs 81% F24 23% vs 19% F24 85% vsvs 81% 78% <, F24 77% F24 15% 23% vs 19% <, vs 22% F24 Formulations VS PFI Mix % NIP + OTF Mix % Formulations PFI NIP + OTF Other Products 35% vs -45% F24
Slide 7: Manufacturing Process Capabilities
MANUFACTURING PROCESS CAPABILITIES x x STABILITY TRANSMUCOSAL FILM BI/MULTI LAYER FILM ACTIVE NANO ENHANCEMENT CASTING CASTING PARTICULATE GRANULATION ORAL FILMS CASTING x SOLVENT LESS SOLUBILITY MULTI LAYERED TASTE MASKING BIOAVAILABILITY PROCESSING PELLETS ENHANCEMENT • ZIM Laboratories Limited's
Slide 8: R&D at Core
R&D AT CORE 85 R&D Expense Mix & as % of Total Operating Income ( ) R&D Team Size 6.5% 5.3% 7.1% 6.6% 9.7% 9.8% 2 100% PhDs 8% 5% 16% 90% 6% 21% 29% 76 80% 3% 24% 43% Postgraduates 8% 70% 16% Rs. 1, 021 Mn 60% 1% Spent in last 4 years on Opex, Facility, and BE 50% Studies 86% 40% 81% 71% 71% 30% 4 5
Slide 9: NIP & OTF Revenue Performance
NIP & OTF REVENUE PERFORMANCE NIP Revenue (₹ Mn) & NIP Contribution to Total Operating Income OTF Revenue (₹ Mn) & OTF Contribution to Total Operating Income (%) (%) 18.6% 4.3% 3.4% 3.4% 3.3% 2.6% 2.7% 6.2% 3.1% 8.4% 6.9% 1.9% 4.5% 5.1% 1.1% 1.6% 0.9% 0.8% 37 33 39 26 27 23 26 11 8 45 17 47 72 49 73
Slide 10: Growing Finished Formulations Business
GROWING FINISHED FORMULATIONS BUSINESS Finished Formulation (₹ Mn) & Revenue % Contribution PFI (₹ Mn ) & Revenue % Contribution 52% 46% 70% 68% 44% 42% 60% 60% 61% 40% 58% 59% 51% 38% 57% 37% 36% 36% 54% 53% 35% 29% 44% 27% 540 715 505 646 634 597 433 587 374 403 518 539 502 467 428 289 300 313 255
Slide 11: Technology Platforms - NIP
TECHNOLOGY PLATFORMS - NIP • Versatile and Innovative Technologies • Wide Range of Pharmaceutical Applications • Market Differentiation • Scalable and Cost-Effective Manufacturing • Risk Mitigation • Market Opportunities 10
Slide 12: New Innovative Products Development Timeline
NEW INNOVATIVE PRODUCTS DEVELOPMENT TIMELINE PRODUCT THERAPY Market Size (Ex – USA) REMARKS Product 1 Urology USD 495 Mn Filed in the EU during Q4FY23, and for other markets thereafter Product 2 Gastro-Intestinal USD 637 Mn Product 3 Anti - Coagulant USD 1199 Mn Filed in the EU during Q4FY24 Product
Slide 13: Dedicated Facility for Liquid in Pellet Tech
DEDICATED FACILITY FOR LIQUID IN PELLET TECH Innovative Technology: Proprietary Liquid-in-Pellets (LIP) technology ensures enhanced stability, controlled release, and superior bioavailability for liquid-based formulations. Key Products: •Peppermint Oil (Gastroenterology): Effective for managing IBS
Slide 14: Thank You
a Zeal & novation in Medicine THANK YOU